Trial Profile
Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Doxazosin (Primary) ; Lisinopril (Primary) ; ACE inhibitors; Antihypertensives; Atenolol; Chlortalidone; Diuretics; Pravastatin
- Indications Cardiovascular disorders; Heart failure; Hyperlipidaemia; Hypertension; Stroke
- Focus Therapeutic Use
- Acronyms ALLHAT
- 03 Aug 2022 Results of secondary analysis comparing the use of chlorthalidone, amlodipine, or lisinopril on the primary outcome of combined coronary heart disease, stroke, or all-cause mortality in patients with isolated systolic hypertension or isolated diastolic hypertension, published in the American Heart Journal.
- 01 Aug 2021 Results (n=5234) assessing determine the association between the percentage of visits with sustained BP control and incident high-cost multimorbidity cluster dyads and triads published in the Journal of General Internal Medicine
- 09 May 2020 Results presented at the 2020 Annual Scientific Meeting of the American Geriatrics Society